Cited 74 times in
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신재일 | - |
dc.date.accessioned | 2022-02-23T00:58:36Z | - |
dc.date.available | 2022-02-23T00:58:36Z | - |
dc.date.issued | 2021-07 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/187471 | - |
dc.description.abstract | Tumor mutational burden (TMB) is a numeric index that expresses the number of mutations per megabase (muts/Mb) harbored by tumor cells in a neoplasm. TMB can be determined using different approaches based on next-generation sequencing. In the case of high values, it indicates a potential response to immunotherapy. In this systematic review, we assessed the potential predictive role of high-TMB in pancreatic ductal adenocarcinoma (PDAC), as well as the histo-molecular features of high-TMB PDAC. High-TMB appeared as a rare but not-negligible molecular feature in PDAC, being present in about 1.1% of cases. This genetic condition was closely associated with mucinous/colloid and medullary histology (p < 0.01). PDAC with high-TMB frequently harbored other actionable alterations, with microsatellite instability/defective mismatch repair as the most common. Immunotherapy has shown promising results in high-TMB PDAC, but the sample size of high-TMB PDAC treated so far is quite small. This study highlights interesting peculiarities of PDAC harboring high-TMB and may represent a reliable starting point for the assessment of TMB in the clinical management of patients affected by pancreatic cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | CANCERS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pediatrics (소아과학교실) | - |
dc.contributor.googleauthor | Rita T Lawlor | - |
dc.contributor.googleauthor | Paola Mattiolo | - |
dc.contributor.googleauthor | Andrea Mafficini | - |
dc.contributor.googleauthor | Seung-Mo Hong | - |
dc.contributor.googleauthor | Maria L Piredda | - |
dc.contributor.googleauthor | Sergio V Taormina | - |
dc.contributor.googleauthor | Giuseppe Malleo | - |
dc.contributor.googleauthor | Giovanni Marchegiani | - |
dc.contributor.googleauthor | Antonio Pea | - |
dc.contributor.googleauthor | Roberto Salvia | - |
dc.contributor.googleauthor | Valentyna Kryklyva | - |
dc.contributor.googleauthor | Jae Il Shin | - |
dc.contributor.googleauthor | Lodewijk A Brosens | - |
dc.contributor.googleauthor | Michele Milella | - |
dc.contributor.googleauthor | Aldo Scarpa | - |
dc.contributor.googleauthor | Claudio Luchini | - |
dc.identifier.doi | 10.3390/cancers13133119 | - |
dc.contributor.localId | A02142 | - |
dc.relation.journalcode | J03449 | - |
dc.identifier.eissn | 2072-6694 | - |
dc.identifier.pmid | 34206554 | - |
dc.subject.keyword | PD-1 | - |
dc.subject.keyword | PD-L1 | - |
dc.subject.keyword | TMB | - |
dc.subject.keyword | TML | - |
dc.subject.keyword | immunotherapy | - |
dc.subject.keyword | pancreatic cancer | - |
dc.subject.keyword | tumor mutation burden | - |
dc.contributor.alternativeName | Shin, Jae Il | - |
dc.contributor.affiliatedAuthor | 신재일 | - |
dc.citation.volume | 13 | - |
dc.citation.number | 13 | - |
dc.citation.startPage | 3119 | - |
dc.identifier.bibliographicCitation | CANCERS, Vol.13(13) : 3119, 2021-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.